Synthesis, structural analysis and anticonvulsant activity of a ternary Cu(II) mononuclear complex containing 1,10-phenanthroline and the leading antiepileptic drug valproic acid

Biochimie

Volumn 91, Issue 10, 2009, Pages 1286-1293

  Sylla Iyarreta Veitía, Maité ^a   Dumas, Françoise ^a   Morgant, Georges ^a,b   Sorenson, John R J ^c   Frapart, Yves ^d   Tomas, Alain ^e  

^a UNIVERSITÉ PARIS SUD   (France)

^b ARMAND TROUSSEAU HOSPITAL   (France)

^c UNIVERSITY OF ARKANSAS AT LITTLE ROCK   (United States)

^d UNIVERSITÉ PARIS DESCARTES   (France)

^e UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

Anticonvulsant properties; Central nervous system; Copper(II) complex; Slipped Stacking; Valproic acid

Indexed keywords

1,10 PHENANTHROLINE; ANTICONVULSIVE AGENT; BIS(2 PROPYLPENTANOATE)(1,10 PHENANTHROLINE)COPPER; CARBOXYLIC ACID DERIVATIVE; COORDINATION COMPOUND; COPPER DERIVATIVE; UNCLASSIFIED DRUG; VALPROIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICONVULSANT ACTIVITY; ARTICLE; CHELATION; CHEMICAL BOND; CLONIC SEIZURE; CONTROLLED STUDY; CRYSTAL STRUCTURE; DRUG EFFECT; DRUG EFFICACY; DRUG MEGADOSE; DRUG STRUCTURE; DRUG SYNTHESIS; MOUSE; NONHUMAN; PETIT MAL; RAT; SEIZURE;

MUS;

ANIMALS; ANTICONVULSANTS; COPPER; CRYSTALLOGRAPHY, X-RAY; ELECTRON SPIN RESONANCE SPECTROSCOPY; MALE; MICE; MOLECULAR STRUCTURE; ORGANOMETALLIC COMPOUNDS; PHENANTHROLINES; RATS; SEIZURES; VALPROIC ACID;

EID: 69949086565     PISSN: 03009084     EISSN: 61831638     Source Type: Journal    
DOI: 10.1016/j.biochi.2009.06.015     Document Type: Article

References (54)

1. Cotton F.A., Wilkinson G., Murillo C.A., and Bochman M. Advanced Inorganic Chemistry. sixth ed. (1999), John Wiley, New York pp. 873-875
2. Neumann P.F., and Silverberg M. Metabolic pathways of red blood cell copper in normal humans and in Wilson's disease. Nature 213 (1967) 775-779
3. Sternlieb I., Van den Hamer C.J., and Alpert S. Role of intestinal lymphatic's in copper absorption. Nature 216 (1967) 824
4. Underwood E.J. Trace Elements in Human and Animal Nutrition. third ed. (1961), Academic Press, New York, N.Y
5. Sorenson J.R. Copper chelates as possible active forms of the antiarthritic agents. J. Med. Chem. 19 (1976) 135-148
6. Sorenson J.R. Copper complexes offer a physiological approach to treatment of chronic diseases. Prog. Med. Chem. 26 (1989) 437-568
7. Kovala-Demertzi D. Transition metal complexes of diclofenac with potentially interesting anti-inflammatory activity. J. Inorg. Biochem. 79 (2000) 153-157
8. Alsarra I.A., Al-Omar M., and Belal F. Prof. Drug Subst. Excip. Rel. Meth. 32 (2005) 209-240
9. Chapman A.G., Keane P.E., Meldrum B.S., Simiand J., and Vernieres J.C. Mechanism of anticonvulsant action of valproate. Prog. Neurobiol. 19 (1982) 315-359
10. Loscher W. Prog., Valproate: a reappraisal of its pharmacodynamic properties and mechanisms of action. Neurobiol. 58 (1999) 31-59
11. Misra U.K., Kalita J., and Patel R. Sodium valproate vs phenytoin in status epilepticus: a pilot study. Neurology 67 (2006) 340-342
12. DeVane C.L. Pharmacokinetics, drug interactions, and tolerability of valproate. Psychopharmacol. Bull. 37 (2003) 25-42
13. Kennedy D., and Koren G. Valproic acid use in psychiatry: issues in treating women of reproductive age. J. Psychiatry Neurosci. 23 (1998) 223-228
14. Kessem A., Musafia B., and Ben-Tal N. Continuum solvent model studies of the interactions of an anticonvulsant drug with a lipid bilayer. Biophys. J. 80 (2001) 2536-2545
15. Wiltse J. Mode of action: inhibition of histone deacetylase, altering WNT-dependent gene expression, and regulation of beta-catenin-developmental effects of valproic acid. Crit. Rev. Toxicol. 35 (2005) 727-728
16. De Felice L., Tatarelli C., Mascolo M.G., Gregorj C., Agostini F., Fiorini R., Gelmetti V., Pascale S., Padula F., Petrucci M.T., Arcesse W., and Nervi C. Histone deacetylase inhibitor valproic acid enhances the cytokine-induced expansion of human hematopoietic stem cells. Cancer Res. 65 (2005) 1505-1513
17. Ylisastigui L., Coull J.J., Rucker V.C., Melander C., Bosch R.J., Brodie S.J., Corey L., Sodora D.L., Dervan P.B., and Margolis D.M. Polyamides reveal a role for repression in latency within resting T cells of HIV-infected donors. J. Infect. Dis. 190 (2004) 1429-1437
18. Lehrman G., Hogue I.B., Palmer S., Jennings C., Spina C.A., Wiegand A., Landay A.L., Coombs R.W., Richman D.D., Mellors J.W., Coffin J.M., Bosch R.J., and Margolis D.M. Depletion of latent HIV-1 infection in vivo: a proof-of-concept study. Lancet 366 (2005) 549-555
19. Routy J.P. Valproic acid: a potential role in treating latent HIV infection. Lancet 366 (2005) 523-524
20. Smith S.M. Valproic acid and HIV-1 latency: beyond the sound bite. Retrovirology 2 (2005) 1-3
21. Feng W., and Kenney C. Valproic acid enhances the efficacy of chemotherapy in EBV-positive tumors by increasing lytic viral gene expression. Cancer Res. 66 (2006) 8762-8769
22. Dutheil F., Beaune P., and Loriot M.-A. Xenobiotic metabolizing enzymes in the central nervous system: contribution of cytochrome P450 enzymes in normal and pathological human brain. Biochimie 90 (2008) 426-436
23. Verrotti A., Greco R., Latini G., and Chiarelli F. Endocrine and metabolic changes in epileptic patients receiving valproic acid. J. Pediatr. Endocrinol. Metab. 18 (2005) 423-430
24. Sobol E., Bialer M., and Yagen B. Tetramethylcyclopropyl analogue of a leading antiepileptic drug, valproic acid. Synthesis and evaluation of anticonvulsant activity of its amide derivatives. J. Med. Chem. 47 (2004) 4316-4326
25. Blaheta R.A., Nau H., Michaelis M., and Cinatl J.J. Valproate and valproate-analogues: potent tools to fight against cancer. Curr. Med. Chem. 9 (2002) 1417-1433
26. Houben M.L., Wilting I., Stroink H., and van Dijken P.J. Pancreatitis, complicated by a pancreatic pseudocyst associated with the use of valproic acid. Eur. J. Paediatr. Neurol. 9 (2005) 77-80
27. Walia K.S., Khan E.A., Ko D.H., Raza S.S., and Khan Y.N. Side effects of antiepileptics - a review. Pain Pract. 4 (2004) 194-203
28. Trojnar M.K., E.Wierzchowska-Cioch M., Krzyzanowski M., and Jargiello-Czuczwar S.J. New generation of valproic acid. Polish J. Pharmacol. 56 (2004) 283-288
29. Bialer M., Haj-Yehia A., Badir K., and Hadad S. Can we develop improved derivatives of valproic acid?. Pharm. World Sci. 16 (1994) 2-6
30. Ranford J.D., Salder P.J., and Tocher D.A. Cytotoxicity and antiviral activity of transition-metal salicylato complexes and crystal structure of Bis(diisopropylsalicylato)(1,10-phenanthroline)copper(II). J. Chem. Soc. Dalton Trans. (1993) 3393-3399
31. MacLeod R. The toxicity of o-phenanthroline for lactic acid bacteria. J. Biol. Chem. 197 (1952) 751-761
32. Shulman A., and White D.O. Virostatic activity of 1,10-phenanthroline transition metal chelates: a structure-activity analysis. Chem. Biol. Interact. 6 (1973) 407-413
33. Shulman A., and Laycock G.M. Action of 1,10-phenanthroline transition metal chelates on P388 mouse lymphocyte leukaemic cells. Chem. Biol. Interact. 16 (1977) 89-99
34. Barton J.K. Metals and DNA: molecular left-handed complements. Science 233 (1986) 727-734
35. Lemoine P., Viossat B., Morgant G., Greenaway F.T., Tomas A., Dung N.H., and Sorenson J.R.J. Synthesis, crystal structure, EPR properties, and anti-convulsant activities of binuclear and mononuclear 1,10-phenanthroline and salicylate ternary copper(II) complexes. J. Inorg. Biochem. 89 (2002) 18-28
36. Lemoine P., Viossat B., Dung N.H., Tomas A., Morgant G., Greenaway F.T., and Sorenson J.R.J. Synthesis, crystal structures, and anti-convulsant activities of ternary [Zn(II)(3,5-diisopropylsalicylate)(2)], [Zn(II)(salicylate)(2)] and [Zn(II)(aspirinate)(2)] complexes. J. Inorg. Biochem. 98 (2004) 1734-1749
37. Otwinowski Z., Minor W., Carter Jr. C.W., and Sweet R.M. Methods & Enzymology. Macromolecular Crystallography, Part A vol. 276 (1997), Academic Press, New York pp. 307-326
38. Altomare A., Burla M.C., Camalli M., Cascarano G.L., Giacovazzo G., Guagliardi A., Moliterni A.G.G., Polidori G., and Spagna R. SIR97: a new tool for crystal structure determination and refinement. J. Appl. Crystallogr. 32 (1999) 115-119
39. Sheldrick G.M. SHELXL-97, Program for Crystal Structure Refinement (1997), University of Göttingen, Germany
40. Watkin D.J., Prout C.K., and Pearce L.J. CAMERON, Chemical Crystallography Laboratory (1996), University of Oxford, UK
41. ®. A computer simulation software suite (v. 1.1.3) for the analysis of continuous wave EPR spectra. J. Inorg. Biochem. 98 (2004) 903-916
42. Christidis P.C., Rentzeperis P.J., Sigalas M.P., and Hadjikostas C.C. Crystal structure and spectra of bis(μ-valproato-O, O')(pyridine)copper(II), C42H70Cu2N2O8. Zeitschrift Für Kristallographie 176 (1986) 103-112
43. Hadjikostas C.C., Katsoulos G.A., Sigalas M.P., Tsipis C.A., and Mroziński J. Spectral and magnetic characterization of amine adducts of copper(II) valproate. Inorg. Chim. Acta 167 (1990) 165-169
44. Abuhijleh A.L., and Woods C. Characterization and catecholase-mimetic behavior of imidazole adducts of copper (II) valproate. Crystal structure of the 2-methylimidazole adduct. Inorg. Chim. Acta 209 (1993) 187-193
45. Abuhijleh A.L. Catalytic activities of the antitumour complex bis(acetato) bis(imidazole)copper(II) and bis(valproato)bis(imidazole)copper(II) for the oxidation of organic substrates. Polyhedron 15 (1996) 285-293
46. Abuhijleh A.L., and Woods C. Synthesis, characterization, and oxidase activities of copper(II) complexes of the anticonvulsant drug valproate. J. Inorg. Biochem. 64 (1996) 55-67
47. Abuhijleh A.L. Ternary copper(II) complexes of the anticonvulsant drug valproate with diimines as superoxide dismutase mimics. J. Inorg. Biochem. 68 (1997) 167-175
48. Grapperhaus C.A., Mullins C.S., Kozlowski P.M., and Mashuta M.S. Structure of metal-ligand covalency from the bonding in carboxylate ligands. Inorg. Chem. 43 (2004) 2859-2866
49. Hocking R.K., and Hambley T.W. Structural Measure of metal-ligand covalency from the bonding in carboxylate ligands. Inorg. Chem. 42 (2003) 2833-2835
50. Muhonen H., and Hamäläinen R. The crystal and molecular structure of bis (salicylato)(N, N, N', N'-tetramethylethylenediamine)copper(II). Acta Cryst. B 34 (1978) 1842-1846
51. Kaizer J., Csay T., Speier G., Réglier M., and Giorgi M. Synthesis, structure and catalase-like activity of Cu(N-baa)2(phen) (phen = 1,10-phenanthroline, N-baaH = N-benzoylanthranilic acid). Inorg. Chem. Commun. 9 (2006) 1037-1039
52. White H., Woodhead J.H., Wilcox K.S., Stables J.P., Kupferberg H.J., and Wolf H.H. Antiepileptic Drugs. fifth ed.. (2002), Lippincott Williams & Wilkins Publishers, New York pp. 36-48
53. Huseyin U., Kim V.D., Silvia C., Santi S., James P.S., Paul D., I.MajedBernard M., and Jacques H.P. Synthesis and anticonvulsant activity of 2(3H)-Benzoxazolone and 2(3H)-Benzothiazolone derivatives. J. Med. Chem. 41 (1998) 1138-1145
54. Pandeya S.N., Raja A.S., and Stables J.P. Synthesis of isatin semicarbazones as novel anticonvulsants-role of hydrogen bonding. J. Pharm. Pharmaceut. Sci. 5 (2002) 266-271